The FDA’s authorization of the Q-Collar is under scrutiny after researchers identified duplicated data, altered study endpoints, and unsubstantiated “brain protection” claims.
October 2025 highlights in the small molecules sector include developments in dermatitis treatment, improvements in epilepsy symptoms, and the effects of amoxicillin availability.